Companies › Insmed Gene Therapy
2 active drug programs in 2 registered trials: 2 Phase 1; Neurology; next expected readout Jan 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| INS1201 Gene therapy for Duchenne muscular dystrophy | DMD | Phase 1 | Duchenne Muscular Dystrophy | Jan 2028 |
| INS1202 Gene therapy targeting SOD1 mutations | SOD1 | Phase 1 | Amyotrophic Lateral Sclerosis | Mar 2030 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06817382 | INS1201 | Phase 1 | Duchenne Muscular Dystrophy | Neurology | Jan 2028 |
| NCT07290062 | INS1202 | Phase 1 | Amyotrophic Lateral Sclerosis | Neurology | Mar 2030 |
Solid Biosciences NS Pharma Sarepta Therapeutics UniQure Biopharma Biogen Regeneron Pharmaceuticals Dyne Therapeutics Avidity Biosciences REGENXBIO Precision BioSciences
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.